New hope for teens fighting relapsed bone cancer
NCT ID NCT02243605
Summary
This study is testing an oral drug called cabozantinib to see if it can control the growth of two aggressive bone cancers, osteosarcoma and Ewing sarcoma, in young patients whose cancer has returned or spread after standard treatment. The drug works by blocking signals tumors need to grow and by cutting off their blood supply. The main goal is to see if the treatment can stop the cancer from getting worse for at least six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Strasbourg - Hospital Civil
Strasbourg, 67091, France
-
Center Claudius Regaud
Toulouse, 31052, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Georges-Francois Leclerc
Dijon, 21079, France
-
Centre Leon Berard
Lyon, 69373, France
-
Centre Oscar Lambert
Lille, 59020, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hopital De La Timone
Marseille, 13385, France
-
Institut Bergonie Cancer Center
Bordeaux, 33076, France
-
Institut Curie Paris
Paris, 75005, France
-
Institut de Cancerologie de l'Ouest-Rene Gauducheau
Saint-Herblain, 44805, France
Conditions
Explore the condition pages connected to this study.